Literature DB >> 3409241

Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

S K Mauldin1, G Gibbons, S D Wyrick, S G Chaney.   

Abstract

We have previously reported the development of a two-column high performance liquid chromatography system for separation of platinum(II) complexes with the 1,2-diaminocyclohexane (DACH) carrier ligand (Mauldin et al., Anal. Biochem., 157: 129, 1986). Here we report the application of this technique to the study of the intracellular biotransformations of (DL)-trans-1,2-diaminocyclohexanemalonatoplatinum(II) [PtCl2(trans-DACH)] and (DL)-trans-1,2-diaminocyclohexanemalonatoplatinum(II) [Pt(mal)(trans-DACH)] in the L1210 cell line. The two-column high performance liquid chromatography system allowed separation and identification of both parent drugs and intracellular biotransformation products containing glutathione, methionine, cysteine, arginine, lysine, aspartate or glutamate, and serine or threonine. With the exception of the platinum-glutathione complex, the relative abundance of each biotransformation product was independent of drug concentration. The relative abundance of the platinum-glutathione biotransformation product increased with increasing platinum concentration, suggesting that platinum drugs cause an increase in intracellular glutathione levels in a dose-dependent manner. This hypothesis was verified by direct measurement of intracellular glutathione levels. In continuous uptake experiments, the intracellular levels of the parent compounds peaked between 2 and 5 h and declined to negligible levels by 24 h. In pulse-chase experiments, the chemical t1/2 for PtCl2(trans-DACH) and Pt(mal)(trans-DACH) inside the cell at 37 degrees C was determined to be 12-15 and 21-28 min, respectively. This is far shorter than previously determined rates for the displacement of either ligand in vitro. The platinum-amino acid complexes accumulated gradually throughout the 24-h incubation. The free trans-DACH carrier ligand also accumulated to a level approaching 20% of filterable counts during the 24-h incubation, probably due to trans-labilization of the carrier ligand by sulfur-containing nucleophiles. A combination of reverse phase high performance liquid chromatography and a DNA binding assay was used to identify and quantitate the reactive biotransformation products. As expected from previous studies (Mauldin et al., Cancer Res., 46: 2876, 1986), the PtCl2(trans-DACH)-treated cells had approximately 3 times more reactive platinum biotransformation product at early times, but the levels of reactive biotransformation product fell much more rapidly than in Pt(mal)(trans-DACH)-treated cells. In the PtCl2(trans-DACH)-treated cells, the major reactive biotransformation product was the aquachloro species at all time points tested. In Pt(mal)(trans-DACH)-treated

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.

Authors:  C L King; S Ramachandran; S G Chaney; L Collins; J A Swenberg; K E DeKrafft; W Lin; L Cicurel; M Barbier
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

Review 2.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 3.  New cisplatin analogues in development. A review.

Authors:  Raymond B Weiss; Michaele C Christian
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.

Authors:  S S Daoud; N H Forde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Authors:  D C Thompson; A Vaisman; M K Sakata; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Chemical stability, biological activity and cellular uptake of a cisplatin analogue having a 1,2-diarylethyleneamine ligand in cultures of human breast cancer cells.

Authors:  A M Otto; N A Kratochwil; H Eggers; P J Bednarski
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.

Authors:  P F Carfagna; A Poma; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.

Authors:  Hong-Yan Zhang; Yu-Ru Liu; Chao Ji; Wei Li; Shuo-Xing Dou; Ping Xie; Wei-Chi Wang; Ling-Yun Zhang; Peng-Ye Wang
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

10.  Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.

Authors:  D Screnci; H M Er; T W Hambley; P Galettis; W Brouwer; M J McKeage
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.